PharmaEssentia USA Corporation announced FDA approval and the U.S. launch of the BESREMi Pen device for adult patients with polycythemia vera. The new pre-filled pen offers a more convenient self-administration option compared to the currently available pre-filled syringe and is expected to become commercially available in the coming weeks. Samuel Lin, Head of Global Operations at PharmaEssentia, called the approval a significant milestone that empowers patients to manage their condition with greater ease and confidence. Dr. John Mascarenhas of Mount Sinai noted the device has the potential to simplify self-administration and support better treatment adherence.
PharmaEssentiaFDA approval and U.S. launch of BESREMi Pen, a new self-administration device for polycythemia vera.